Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.
종목 코드 DNA
회사 이름Ginkgo Bioworks Holdings Inc
상장일Apr 19, 2021
CEODr. Jason Kelly
직원 수834
유형Ordinary Share
회계 연도 종료Apr 19
주소27 Drydock Avenue
도시BOSTON
증권 거래소NYSE Consolidated
국가United States of America
우편 번호02210
전화18774425362
웹사이트https://investors.ginkgobioworks.com/
종목 코드 DNA
상장일Apr 19, 2021
CEODr. Jason Kelly
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음